We found that the administration of Dexamethasone in vitro on exacerbated COPD-derived PBMCs was not able to revert the detrimental inflammatory mechanism associated with AIM2 activation responsible for the release of IL-1α and the ensuing TGF-β, contributing to the severity of the disease. The gene discussed is IL1A; the disease is chronic obstructive pulmonary disease.